SUPN

SUPERNUS PHARMACEUTICALS

SUPN·868459108·US·Common Stock·Healthcare - Drug Manufacturers - Specialty & Generic-13D/G

SUPN (SUPERNUS PHARMACEUTICALS) is held by 153 institutional investors as of Q2 2026. Largest holders: BlackRock, Inc. ($434.9M), MILLENNIUM MANAGEMENT LLC ($179.2M), VANGUARD PORTFOLIO MANAGEMENT LLC ($153.7M). Net institutional sentiment: Mixed. In Q2 2026, 1 member of Congress and 78 funds bought SUPN.

153
Holders
(12 Elite)
$2.3B
Total Value
49% (160)
Consensus
78 buying - 82 selling
13F: Insider & Congress: Updated regularly
SUPN

Smart Money Verdict

View all
Loading verdict
Held by 153 funds
12 elite

Who's Trading

Source dates: Price Sep 21, 2026 · Insiders Aug 14, 2026 · Activists Aug 6, 2026 · Congress Apr 7, 2026

InsiderMFMottola FrankExercise 2K shAug 12, 2026
InsiderDCDEC TIMOTHY CTax 604 shAug 12, 2026
InsiderBPBhatt Padmanabh P.Exercise 3K shAug 12, 2026
Checking access…

Top Holders

Checking access…
Action
Increased
9.4M(+6.3%)$434.9M0.0%+9.65%
33
Increased
3.9M(+16.2%)$179.2M0.1%-17.40%
35
Increased
3.3M(+2.1%)$153.7M0.0%-24.11%
31
Increased
2.5M(+2.0%)$117.1M0.0%-24.12%
31
Increased
2.5M(+7.5%)$114.4M0.0%+32.30%
32
Increased
2.4M(+16.7%)$110.6M0.2%-16.45%
42
Decreased
2.1M(-9.9%)$96.7M0.0%+19.51%
0
Decreased
1.6M(-3.3%)$73M0.0%+28.07%
0
Decreased
1.5M(-13.3%)$68.8M0.1%+53.36%
0
Increased
1.5M(+3.5%)$68.6M0.1%+22.80%
31
Decreased
1.4M(-8.0%)$63.9M0.0%-20.29%
0
Increased
1.2M(+336.7%)$55.1M0.0%-12.69%
47
Increased
922,166(+85.1%)$42.9M0.0%-11.45%
45
Decreased
876,841(-4.0%)$40.8M0.0%+17.10%
0
Decreased
819,432(-4.3%)$38.1M0.0%-3.02%
0
Increased
767,668(+23.3%)$35.7M0.0%+5.52%
35
Increased
733,374(+4.8%)$34.1M0.0%+16.96%
30
Increased
708,276(+57.8%)$32.9M0.1%-20.02%
49
Decreased
703,552(-0.3%)$32.7M0.0%+35.16%
0
Decreased
621,102(-13.0%)$28.9M0.0%-6.77%
0

Showing 1-20 of 171

1 / 9
SUPNSUPNSUPERNUS PHARMACEUTICALS

Other Healthcare stocks held by institutions

Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used